Here are the DEF 14A proxy statements from Estrella Immunopharma, Inc. (ESLA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ESLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLA filings page.
Estrella Immunopharma, Inc. is holding a virtual Combined 2025/2026 Annual Meeting of Stockholders on June 29, 2026 at 10:00 a.m. Eastern Time, asking stockholders to ratify the appointment of Macias Gini & O’Connell LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
The record date is May 20, 2026, when 43,034,228 shares of common stock were outstanding and entitled to vote. The proxy statement explains online participation and advance question procedures and shows that Eureka Therapeutics, Inc. beneficially owns 58.7% of the common stock, with Armistice Capital, LLC at 9.9%.